Are the adverse effects of glitazones linked to induced testosterone deficiency? by Carruthers, M et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
Cardiovascular Diabetology
Open Access Hypothesis
Are the adverse effects of glitazones linked to induced testosterone 
deficiency?
M Carruthers*1, TR Trinick2, E Jankowska3,4,5 and AM Traish6
Address: 1Centre for Men's Health, 20/20 Harley Street, London, UK, 2Department of Chemical Pathology, The Ulster Hospital, Belfast, (TRT) UK, 
3Cardiology Department, Military Hospital, Wroclaw, Poland, 4Institute of Anthropology, Polish Academy of Sciences, Wroclaw, Poland, 
5National Heart and Lung Institute, Imperial College, London, (EJ) UK and 6Institute for Sexual Medicine, Boston University School of Medicine, 
Center for Advanced Biomedical Research, Boston, (AMT) USA
Email: M Carruthers* - carruthers@centreformenshealth.co.uk; TR Trinick - tom.trinick@ucht.n-i.nhs.uk; 
E Jankowska - ewa.jankowska@antro.pan.wroc.pl; AM Traish - atraish@bu.edu
* Corresponding author    
Abstract
Background: Adverse side-effects of the glitazones have been frequently reported in both clinical and
animal studies, especially with rosiglitazone (RGZ) and pioglitazone (PGZ), including congestive heart
failure, osteoporosis, weight gain, oedema and anaemia. These led to consideration of an evidence-based
hypothesis which would explain these diverse effects, and further suggested novel approaches by which
this hypothesis could be tested.
Presentation of hypothesis: The literature on the clinical, metabolic and endocrine effects of glitazones
in relation to the reported actions of testosterone in diabetes, metabolic syndrome, and cardiovascular
disease is reviewed, and the following unifying hypothesis advanced: "Glitazones induce androgen deficiency
in patients with Type 2 Diabetes Mellitus resulting in pathophysiological changes in multiple tissues and organs
which may explain their observed clinical adverse effects." This also provides further evidence for the
lipocentric concept of diabetes and its clinical implications.
Testing of the hypothesis: Clinical studies to investigate the endocrine profiles, including
measurements of TT, DHT, SHBG, FT and estradiol, together with LH and FSH, in both men and women
with T2DM before and after RGZ and PGZ treatment in placebo controlled groups, are necessary to
provide data to substantiate this hypothesis. Also, studies on T treatment in diabetic men would further
establish if the adverse effects of glitazones could be reversed or ameliorated by androgen therapy. Basic
sciences investigations on the inhibition of androgen biosynthesis by glitazones are also warranted.
Implications of the hypothesis: Glitazones reduce androgen biosynthesis, increase their binding to
SHBG, and attenuate androgen receptor activation, thus reducing the physiological actions of
testosterone, causing relative and absolute androgen deficiency. This hypothesis explains the adverse
effects of glitazones on the heart and other organs resulting from reversal of the action of androgens in
directing the maturation of stem cells towards muscle, vascular endothelium, erythroid stem cells and
osteoblasts, and away from adipocyte differentiation. The higher incidence of side-effects with RGZ than
PGZ, may be explained by a detailed study of the mechanism by which glitazones down-regulate androgen
biosynthesis and action, resulting in a state of androgen deficiency.
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Background
Recent clinical studies have raised serious concerns
regarding the safety of glitazones, especially rosiglitazone
(RGZ) and pioglitazone (PGZ) to regulate hyperglycemia
in diabetic patients. A meta-analysis study [1] demon-
strated use of RGZ was associated with a "significant
increase in the risk of myocardial infarction and with an
increase in the risk from cardiovascular causes that had border-
line significance". These side effects were confirmed by
other clinical studies[2] and meta-analyses[3], though
some investigators, particularly those reporting the effects
of PGZ treatment [4,5] showed reductions in cardiac
deaths.
Because of the widespread use of glitazones, it is of con-
siderable practical importance to understand the potential
mechanisms underlying the differing effects of these two
thiazolidines on clinical endpoints, in spite of their appar-
ent similar effectiveness in reducing blood glucose, as well
as their wide range of adverse side-effects, including
weight gain, anaemia and osteoporosis. These links
between the clinical, metabolic and endocrine effects of
glitazones give rise to a unifying hypothesis based on
reduction of testosterone biosynthesis and function
Presentation of hypothesis
A Unifying Hypothesis Linking the Adverse Effects of 
Glitazones to Induced Testosterone Deficiency
We advance the following unifying hypothesis: "Glitazones
induce androgen deficiency in patients with Type 2 Diabetes
Mellitus resulting in pathophysiological changes in multiple tis-
sues and organs which may explain their observed clinical
adverse effects." (Figure 1).
It also provides further evidence for Ungar's theory of the
'Lipocentric Pathway to Hyperglycemia', and explains the
toxic ectopic fat distribution in multiple organs, together
with its clinical implications [6].
Evidence Supporting this Hypothesis
A. Epidemiological Studies
There is increasingly considered that low T levels in men
play an important role in the causation of T2DM, and are
associated with reduced insulin sensitivity [7]. In men, cir-
culating T is inversely related to classical cardiovascular
Unifying hypothesis linking the adverse effects of glitazones to induced testosterone deficiency Figure 1
Unifying hypothesis linking the adverse effects of glitazones to induced testosterone deficiency. Testosterone, 
either directly or by conversion to dihydrotestosterone or oestradiol, all largely regulated by the effect of Sex Hormone Bind-
ing Globulin, acts on the Multipotent Stem Cell to promote differentiation to the progenitor cells for muscle, endothelium, 
bone, and red blood cells. By causing androgen deficiency, glitazones may reverse these effects and promote adipocyte produc-
tion and action, with adverse clinical side-effects.Cardiovascular Diabetology 2008, 7:30 http://www.cardiab.com/content/7/1/30
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disease (CVD) risk factors, including dyslipidaemia,
hypertension, pro-thrombotic and pro-inflammatory
states, insulin resistance, obesity, abdominal fat distribu-
tion, endothelial dysfunction, intima-media thickness of
the carotid artery and thoracic aorta [8-12]. Men with cor-
onary artery disease (CAD) confirmed by angiography
have a markedly reduced level of circulating T as com-
pared to those with normal coronary arteries [13-18].
B. Suppression Therapy
Management of prostate cancer via androgen-deprivation
therapy with surgical or medical castration rapidly
induces diabetes in susceptible individuals and is associ-
ated with cardiovascular events [19]. Androgen suppres-
sion therapy for prostate cancer has been linked to an
increased incidence of coronary heart disease and risk fac-
tors for atherosclerosis [20].
C. Treatment in Men
Treatment of diabetic men with T has many beneficial
effects, including increasing insulin sensitivity, correcting
abnormalities in lipid metabolism, especially hypertrig-
lyceridaemia, reducing visceral adiposity, decreasing lep-
tin and adiponectin levels, reversing neuropathy, and
improving erectile function. These effects are largely
brought about by reducing the adverse metabolic effects
of increased adipose tissue in organs throughout the
body, but particularly in abdominal fat, reversing the
actions of the adipocyte as the 'axis of evil' (Fig 2) [21,22]
Beneficial clinical anti-ischaemic effects of T treatment in
men with angina pectoris were reported as early as in the
1940s [23]. Acute T administration reduces exercise-
induced myocardial ischaemia in men with CAD and low
serum testosterone, also prolonging time to ST-segment
depression [24-28].
The metabolic and clinical effects of adipocyte activity Figure 2
The metabolic and clinical effects of adipocyte activity. The adipocyte as the 'Axis of Evil' – PPARγ agonists such as the 
glitazones stimulate the adipocyte to produce adipocytokines and cause insulin resistance, dyslipidaemias, hypertension, and 
impaired immunological responses, which together can have the adverse clinical consequences shown.Cardiovascular Diabetology 2008, 7:30 http://www.cardiab.com/content/7/1/30
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D. Effects on Muscle and Adipocytes
Singh et al [29] suggested that androgens regulate the dif-
ferentiation of multipotent stem cells into the myogenic
lineage and inhibit adipogenesis. They also showed that T
inhibited adipogenic differentiation of pre-adipocytes by
activation of androgen receptor (AR)/beta-catenin interac-
tion and translocation of androgen receptor/beta catenin
complex to the nucleus, thus bypassing canonical Wnt sig-
nalling. These changes can affect all 3 forms of muscle:
Smooth muscle
Ultrastructural studies by Traish et al have documented
that trabecular smooth muscle from castrated animals
appears disorganized, with large number of cytoplasmic
vacuoles and a decrease in myofilaments. Androgen dep-
rivation in the animal model results in accumulation of
adipocytes in penile tissues, particularly in the sub-tunical
region [30]. T replacement restores normal cavernosal his-
tological appearance. Recently, Kovanecz et al [31] have
shown that treatment of obese diabetic Zucker fa/fa rats
with PGZ produced globular fat-like cells in the corpus
cavernosum especially at high doses. These observations
together suggest a link between the function of anti-dia-
betic agents and interference with T action as shown in
Fig. 1.
Striated Muscle
T increases lean body mass and decreases fat mass in
young men, the magnitude of the changes being corre-
lated with T concentrations. Especially in insulin resistant
diabetes, impaired muscle strength and mass is likely to
be associated with the reduction in myoglobin associated
with low T levels.
Cardiac Muscle
Androgen receptors are present in the myocardium (cardi-
omyocytes) and vessel walls[32]. Their expression is mod-
ulated by catecholamines[33] and T itself, as shown by its
depletion in hypertrophied and failing hearts, which is
accompanied by deranged intracardiac steroid metabo-
lism [34]. T deficiency is related to several changes within
the myocardium, including impaired contractility of car-
diomyocytes [34]. All these pathologies can be restored to
normal on T supplementation.
E. Effects on Endothelial Progenitor Cells
T deficiency is associated with a low number of circulating
progenitor cells and endothelial progenitor cells PCs in
young men. T treatment induces an increase in these cells
through a possible direct effect on the bone marrow [35].
F. Effects on Haemopoiesis
T treatment increases red blood cell production and hence
haemoglobin and haematocrit either directly by promot-
ing erythroid stem cell kinetics[36], or indirectly by its
action on erythropoietin[37]. Patients with diabetes tend
to be anaemic, especially the elderly, and their low T is
correlated with their reduced haematocrit[38]. Treatment
with RGZ and PGZ makes them more anaemic, which is
probably related to lower T levels, not haemodilution
[39].
G. Effects on Bone
Because osteoblasts and marrow adipocytes are derived
from a common mesenchymal progenitor, increased adi-
pogenesis may occur at the expense of osteoblasts, leading
to bone loss. RGZ and PGZ usage were associated with
more than doubling of fractures of the hip and wrist,
increasing with the dose of either thiazolidine [40,41].
Potential Mechanisms of Glitazone-Induced Androgen 
Deficiency
The actions of the glitazones on reductions in both TT and
DHT have been shown in healthy men [42]. Troglitazone
(TGZ) interferes with the activity of the P450 cytochrome
oxidase (CPY) enzymes and was taken off the market in
the USA because of its hepatotoxicity. It also increases sex
hormone binding globulin (SHBG) which reduces FT[43].
As detailed in Fig. 1, T either directly, or by its conversion
to DHT or estradiol, regulates the differentiation of
multipotent stem cells into smooth, striated and cardiac
muscle cells, osteoblastic/osteoclastic balance in bone,
haemopoietic activity, and the formation of cytoskeletal
components [30], while inhibiting the differentiation of
progenitor cells into adipocytes.
The higher incidence of side-effects with RGZ than PGZ,
may be further explained by a detailed study of the mech-
anism by which glitazones down-regulate androgen bio-
synthesis [44]. Both RGZ and PGZ changed the steroid
profile of human adrenal NCI-H295R cells and inhibited
the activities of P450c17 and 3betaHSDII, key enzymes of
androgen biosynthesis. PGZ but not RGZ inhibited the
expression of the CYP17 and HSD3B2 genes. Likewise,
PGZ repressed basal and 8-bromo-cAMP-stimulated activ-
ities of CYP17 and HSD3B2 promoter reporters in NCI-
H295R cells. However, PGZ did not change the activity of
a cAMP-responsive luciferase reporter, indicating that it
does not influence cAMP/protein kinase A/cAMP
response element-binding protein pathway signalling.
There is also evidence that PGZ, to a greater extent than
RGZ, increases the maturation of small adipocytes to
larger ones, promoting a reduction in insulin resist-
ance[45], decreasing lipogenesis in the liver, and increas-
ing deposition of fat in the subcutaneous abdominal
tissue, but not visceral fat. PGZ showed an additional ben-
eficial effect on TG, HDL cholesterol and the levels of
small dense LDL compared to RGZ [46].Cardiovascular Diabetology 2008, 7:30 http://www.cardiab.com/content/7/1/30
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Testing of hypothesis
Clinical studies are needed to investigate the endocrine
profiles, including measurements of TT, DHT, SHBG, FT
and oestradiol, together with LH and FSH, in both men
and women with T2DM before and after RGZ and PGZ
treatment in double blind, placebo controlled groups.
Also, further studies on T treatment in diabetic men
would further establish if the adverse effects of glitazones
could be ameliorated by androgen therapy. Basic sciences
investigations on the inhibition of androgen biosynthesis
by glitazones are also warranted.
Implications of the hypothesis
The FDA reports that most PPAR agonists in development
are non-thiazolidinediones, and though more than 50
Innovative New Drug (IND) applications have been filed
for this group of drugs in the last seven years, most devel-
opment programs have been terminated, all for safety rea-
sons, and none have been approved.
This hypothesis explains the adverse effects of glitazones
on the heart and other organs by reducing androgen
action in directing stem cells differentiation into myo-
cytes, vascular endothelium, erythroid stem cells and oste-
oblasts, and promoting adipocyte differentiation. The
adverse clinical effects are directly linked to the metabolic
actions of these drugs. The higher incidence of side-effects
with RGZ compared with PGZ, may be explained by a
detailed study of the mechanism by which glitazones
down-regulate androgen biosynthesis and molecular
mechanism of action, resulting in a state of androgen defi-
ciency.
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